Versant Venture Management LLC's Q3 2023 13F: 1 new position, 1 exit

Form 13F-HR for the quarter ended Sep 30, 2023 · filed Nov 3, 2023 · 8 reported positions · accession 0000950123-23-009395

What changed this quarter

Versant Venture Management LLC's changes in reported equity positions, Q3 2023
Activity Security Weight before Weight now Change Shares Shares %
New RayzeBio, Inc. (RYZB) — 60.9% +60.9 pts +5.16M sh new
Exited CymaBay Therapeutics, Inc. (CBAY) 7.1% — −7.1 pts −544K sh −100%
Reduced Minerva Surgical Inc. (UTRS) 0.5% 0.1% −0.4 pts −1.59M sh −95%

Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled

Top 10 positions — 100.0% of the equity book

Changes in the top 10 this quarter: RYZB entered · CBAY left

# Security Weight before Weight now
1 RayzeBio, Inc. (RYZB) 0.0% 60.9% Entered the top 10
2 Repare Therapeutics, Inc. (RPTX) 33.2% 17.0%
3 CRISPR Therapeutics AG (CRSP) 33.2% 12.0%
4 Adverum Biotechnologies, Inc. (ADVM) 9.6% 4.0%
5 Gritstone Oncology, Inc. (GRTS) 8.2% 3.3%
6 Passage Bio, Inc. (PASG) 5.5% 1.7%
7 Aligos Therapeutics, Inc. (ALGS) 2.7% 0.9%
8 Minerva Surgical Inc. (UTRS) 0.5% 0.1%
— CymaBay Therapeutics, Inc. (CBAY) 7.1% 0.0% Left the top 10

Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).